ICYMI, this week we had articles about the FDA granting priority review of Abeona's pz-cel BLA for recessive DEB, end-of-the-month highlights from the November issue and supplement of Dermatology Times, the FDA accepting Arcutis' sNDA of roflumilast cream 0.15% for AD, and more.
Recently, a significant breakthrough was achieved when 42 international vitiligo experts and 4 patient representatives collaborated and developed a consensus management strategy for vitiligo.
Experts discuss enhancing patient outcomes, comparing clobetasol cream concentrations, and more.
Keep up with the latest headlines in dermatology from the past week, including new research related to eczema and itch linked to bacteria, a new drug developed for melanoma and lung cancer demonstrating potential in the treatment of cSCC, and more.
In this week’s Pointers With Portela, the 208SkinDoc reviews on his podcast why it's dangerous to have moles lasered off before taking a biopsy.
This article compares physicians in general to average US investors in several key areas and examines how these factors affect a dermatologist’s approach to investing and wealth management.
Ted Lain, MD, MBA, moderated a discussion to share strategies to optimize treatment sequencing, reevaluate long-term management, understand barriers to novel therapies, promote prior authorization integration, and diversify treatment areas.
The FDA’s PDUFA target date is May 25, 2024.
As more dermatology clinicians find themselves increasingly exhausted, being in a hurry can lead to legal repercussions.
A phase 1 study found that RPT193 monotherapy led to greater improvements in clinical efficacy than treatment with a placebo.
Identifying social determinants in TEM is crucial to eliminating disparities in care, study authors wrote.
Depression, functional impairment, and worsened quality of life are related in patients with psoriatic disease, according to a recent study.
The sNDA is supported by positive data from the phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials.
A recent study linked alopecia areata and the presence of cochlear dysfunction in some patients.
Each of 3 patients treated with cemiplimab achieved a near complete response.
With greater understanding of this rare pathology and its signs and symptoms, review authors believe this understanding could prompt early and necessary intervention.
Learn more about the in-depth topics covered in the November 2023 print issue of Dermatology Times.
Learn more about the in-depth topics covered in the November 2023 Frontline Forum corticosteroid-responsive dermatoses supplement of Dermatology Times.
The US license period will start on February 22, 2025.
The technology combines the irradiation of two wavelengths at 10,600 nm and 1540 nm.
Click here to answer this week's poll for Hyperhidrosis Awareness Month.
The addition of bemcentinib to the standard-of-care therapies of pembrolizumab or dabrafenib plus trametinib was well tolerated in patients with metastatic melanoma; however, it did not lead to improvements in overall response rate, progression-free survival, or overall survival vs SOC alone.
This World Aids Day, review the common dermatologic manifestations of AIDS and HIV infection.
Investigators also developed a MELASQoL model using 4 predictors of quality of life impacts in patients with melasma.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.